KR950700073A - Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acide (LNAA) - Google Patents

Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acide (LNAA)

Info

Publication number
KR950700073A
KR950700073A KR1019940703100A KR19940703100A KR950700073A KR 950700073 A KR950700073 A KR 950700073A KR 1019940703100 A KR1019940703100 A KR 1019940703100A KR 19940703100 A KR19940703100 A KR 19940703100A KR 950700073 A KR950700073 A KR 950700073A
Authority
KR
South Korea
Prior art keywords
lnaa
carbohydrate
composition
protein
ratio
Prior art date
Application number
KR1019940703100A
Other languages
Korean (ko)
Inventor
리차드 제이 워트만
쥬디스 제이 워트만
Original Assignee
마크에스 부틀러
인터뉴우론 팔마큐티칼스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마크에스 부틀러, 인터뉴우론 팔마큐티칼스 인코퍼레이티드 filed Critical 마크에스 부틀러
Publication of KR950700073A publication Critical patent/KR950700073A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Abstract

혈장에서 거대 중성 아미노산(LNAA)의 식사후 변이를 감소시키는 방법과 이 방법에 유용한 약물을 제공한다. 탄수화물 대 단백질의 비가 3:1 내지 10:1 구체예에서 7:1인 음식과 조성물을 투입하여 LNAA인 약물에 대해 개체별로 약물반응의 다양성을 최소화시킬 수 있다.Provided are methods for reducing post-meal variations of large neutral amino acids (LNAA) in plasma and drugs useful in the methods. Carbohydrate-to-protein ratios in a 3: 1 to 10: 1 embodiment may be added with a 7: 1 food and composition to minimize the diversity of drug responses from individual to individual for LNAA drugs.

Description

거대 중성 아미노산(LNAA)의 혈장농도의 식사후 변이를 감소시키는 방법 및 조성물(Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acid(LNAA)Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acid (LNAA)

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 운동장애와 같은 L-도파독성을 나타내는데 그 정도는 약물주입에 대해 시간간격으로 운동장애가 나타난다. 제2도는 개인별 시간간격에서 혈장 분지쇄 아미노산량(BCCAA)(가령, 이소루이신, 루이신 또는 발린)을 나타내며, 분지쇄 아미노산이 혈장에 가장 풍부한 LNAA 이가 이의 량은 탄수화물 또는 단백질의 섭취에 의해 영향을 받아서, 뇌로의 LNAA의 흡수의 가장 중요한 결정인자가 된다. 혈장 BCAA량에서 변이를 최소화시키기 위한 새로운 식이요법이 혈장 LNAA의 변화에 제동효과를 주는 것으로 나타났다. 제3도는 개인에서 시간별로 혈장 도파/LNAA비(+ - - - +)와 혈장 도파량(o - - - o)을 도표로 나타낸 것이다.FIG. 1 shows L-dopatoxicity such as dyskinesia, with the degree of dyskinesia at time intervals for drug injection. FIG. 2 shows the plasma branched chain amino acid amount (BCCAA) (e.g. isoleucine, leucine or valine) at individual time intervals, and the amount of LNAA divalent, which is the most abundant of branched chain amino acids in plasma, is determined by the intake of carbohydrates or proteins. Affected, it is the most important determinant of LNAA absorption into the brain. New dietary regimens to minimize variation in plasma BCAA levels have been shown to have a braking effect on plasma LNAA changes. FIG. 3 is a graphical representation of the plasma waveguide / LNAA ratio (+---+) and the plasma waveguide dose (o---o) over time in individuals.

Claims (20)

혈장 거대중성 아미노산(LNAA)량의 변화를 감소시키기 위해 개인에 주입하기 위해 탄수화물 대 단백질의 비가 7:1 내지 10:1로 구성된 것을 특징으로 하는 조성물.A composition comprising a carbohydrate-to-protein ratio of 7: 1 to 10: 1 for infusion into an individual to reduce changes in the amount of plasma giant amino acid (LNAA). 제1항에 있어서, LNAA는 루이신, 이소루이신, 발린, 티로신, 페닐알라닌, 트립토판에서 선택되는 것을 특징으로 하는 조성물.The composition of claim 1, wherein the LNAA is selected from leucine, isoleucine, valine, tyrosine, phenylalanine, tryptophan. 제1항에 있어서, 탄수화물 대 단백질의 비가 7:1인 것을 특징으로 하는 조성물.The composition of claim 1, wherein the ratio of carbohydrates to protein is 7: 1. LNAA의 혈장농도의 식사후 변이정도를 감소시키기 위한 방법에 있어서, 탄수화물 대 단백질의 비가 7:1 내지 10:1인 조성물의 효과량을 개인에 투여하는 것을 특징으로 하는 방법.A method for reducing post-meal variation in plasma concentrations of LNAA, characterized in that the individual is administered an effective amount of a composition having a carbohydrate to protein ratio of 7: 1 to 10: 1. 제4항에 있어서, LNAA는 루이신, 이소루이신, 발린, 티로산, 페닐알라닌. 트립토판에서 선택되는 것을 특징으로 하는 방법.The method of claim 4, wherein LNAA is leucine, isoleucine, valine, tyroic acid, phenylalanine. Characterized in that it is selected from tryptophan. 제4항에 있어서, 탄수화물 대 단백질의 비가 7:1인 것을 특징으로 하는 방법.The method of claim 4, wherein the ratio of carbohydrates to protein is 7: 1. LNAA의 혈장농도의 식사후 변이정도를 감소시키기 위한 방법에 있어서, 탄수화물 대 단백질의 비가 7:1 내지 10:1인 음식의 효과량을 개인에 투여하는 것을 특징으로 하는 방법.A method for reducing post-meal variation in plasma concentrations of LNAA, characterized in that the individual is administered an effective amount of a food having a carbohydrate to protein ratio of 7: 1 to 10: 1. 제7항에 있어서, LNAA는 루이신, 이소루이신, 발린, 티로신, 페닐알라닌, 트립토판에서 선택되는 것을 특징으로 하는 방법.8. The method of claim 7, wherein the LNAA is selected from leucine, isoleucine, valine, tyrosine, phenylalanine, tryptophan. 제7항에 있어서, 탄수화물 대 단백질의 비가 7:1인 것을 특징으로 하는 방법.8. The method of claim 7, wherein the carbohydrate to protein ratio is 7: 1. LNAA와 같은 약물에 대한 반응성을 감소시키기 위해 개인에 투여하는 조성물에 있어서 탄수화물 대 단백질의 비율이 3:1 내지 10:1인 것으로 구성된 것을 특징으로 하는 조성물.A composition comprising a carbohydrate to protein ratio of 3: 1 to 10: 1 in a composition administered to an individual to reduce reactivity to drugs such as LNAA. 제10항에 있어서, 약물은 L-도파(레보도파), 알도메트(알파메틸도파)와 5-하이드록시트립토판에서 선택되는 것을 특징으로 하는 조성물.The composition of claim 10, wherein the drug is selected from L-dopa (levodopa), aldomet (alphamethyldopa) and 5-hydroxytryptophan. 제11항에 있어서, 약물이 L-도파인 것을 특징으로 하는 조성물.The composition of claim 11, wherein the drug is L-dopa. 개인별로 다양하게 나타나는 LNAA와 같은 약물에 대한 반응의 다양성을 치료하는 방법에 있어서, 탄수화물 대 단백질의 비가 3:1 내지 7:1인 조성물의 효과량을 투입하는 것으로 구성된 것을 특징으로 하는 방법.A method of treating a variety of responses to drugs, such as LNAA, which vary widely from person to person, characterized in that an effective amount of a composition comprising a carbohydrate to protein ratio of 3: 1 to 7: 1 is introduced. 제13항에 있어서, 약물은 L-도파(레보도파), 알도메트(알파메틸도파)와 5-하이드록시트립토판에서 선택되는 것을 특징으로 하는 방법.The method of claim 13, wherein the drug is selected from L-dopa (levodopa), aldomet (alphamethyldopa) and 5-hydroxytryptophan. 제14항에 있어서, 약물이 L-도파인 것을 특징으로 하는 방법.The method of claim 14, wherein the drug is L-dopa. 제13항에 있어서, 탄수화물 대 단백질의 비가 7:1인 것을 특징으로 하는 방법.The method of claim 13, wherein the carbohydrate to protein ratio is 7: 1. 개인별로 다양하게 나타나는 LNAA와 같은 약물에 대한 반응의 다양성을 치료하는 방법에 있어서, 탄수화물 대 단백질의 비가 3:1 내지 7:1인 음식의 효과량을 투입하는 것으로 구성된 것을 특징으로 하는 방법.A method of treating a variety of reactions to drugs such as LNAA, which vary widely from person to person, characterized in that an effective amount of food in which the carbohydrate to protein ratio is 3: 1 to 7: 1 is introduced. 제17항에 있어서, 약물은 L-도파(레보도파), 알도메트(알파메틸도파)와 5-하이드록시트립토판에서 선택되는 것을 특징으로 하는 방법.18. The method of claim 17, wherein the drug is selected from L-dopa (levodopa), aldomet (alphamethyldopa) and 5-hydroxytryptophan. 제18항에 있어서, 약물이 L-도파인 것을 특징으로 하는 방법.The method of claim 18, wherein the drug is L-dopa. 제17항에 있어서, 탄수화물 대 단백질의 비가 7:1인 것을 특징으로 하는 방법.18. The method of claim 17, wherein the ratio of carbohydrate to protein is 7: 1. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940703100A 1992-03-11 1993-03-11 Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acide (LNAA) KR950700073A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84924692A 1992-03-11 1992-03-11
US849,246 1992-03-11
PCT/US1993/002651 WO1993017670A1 (en) 1992-03-11 1993-03-11 Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa)

Publications (1)

Publication Number Publication Date
KR950700073A true KR950700073A (en) 1995-01-16

Family

ID=25305395

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940703100A KR950700073A (en) 1992-03-11 1993-03-11 Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acide (LNAA)

Country Status (6)

Country Link
EP (1) EP0630238A4 (en)
JP (1) JPH07507058A (en)
KR (1) KR950700073A (en)
AU (1) AU3929493A (en)
CA (1) CA2131801A1 (en)
WO (1) WO1993017670A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698525A (en) * 1989-04-03 1997-12-16 Interneuron Pharmaceuticals, Inc. Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (LNAA)
US5432162A (en) * 1989-04-03 1995-07-11 Interneuron Pharmaceuticals, Inc. Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (LNAA)
IE80469B1 (en) * 1993-09-13 1998-07-29 Elan Corp Plc Compositions for reducing fluctuations in plasma concentrations of large neutral amino acids and use thereof in therapy
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
US7872030B2 (en) 2001-07-26 2011-01-18 Merck Patent Gmbh Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210637A (en) * 1978-07-31 1980-07-01 Massachusetts Institute Of Technology Composition and method for suppressing appetite for calories as carbohydrates
US4542123A (en) * 1982-01-11 1985-09-17 Massachusetts Institute Of Technology Composition and method for increasing brain tyrosine levels
JPS60221043A (en) * 1984-04-18 1985-11-05 Toyo Jozo Co Ltd Feed sugar block and breeding method using same
US4833128A (en) * 1984-12-28 1989-05-23 Neil Solomon Dietary supplement
US4687763A (en) * 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
US4690820A (en) * 1985-06-07 1987-09-01 The State University Of New York High-caloric, high-fat dietary formula
US4639465A (en) * 1985-08-30 1987-01-27 Commonwealth Medical Corporation Of America Method and composition for relieving pain
US5055446A (en) * 1988-10-21 1991-10-08 University Of Cincinnati Method to improve survival of patients during sepsis by diet composition
US5206218A (en) * 1989-04-03 1993-04-27 Interneuron Pharmaceuticals, Inc. Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa)

Also Published As

Publication number Publication date
AU3929493A (en) 1993-10-05
CA2131801A1 (en) 1993-09-16
JPH07507058A (en) 1995-08-03
EP0630238A4 (en) 1995-05-24
WO1993017670A1 (en) 1993-09-16
EP0630238A1 (en) 1994-12-28

Similar Documents

Publication Publication Date Title
Ginguay et al. Indications and contraindications for infusing specific amino acids (leucine, glutamine, arginine, citrulline, and taurine) in critical illness
US11412768B2 (en) Method of improving tolerance to hypoallergenic infant formulas
ES2550463T3 (en) Mixture of tryptophan bound to a peptide and tryptophan bound to a polypeptide
AR015057A1 (en) ELEMENTAL LIQUID FOOD PRODUCT, METHOD FOR PROVIDING NUTRITION TO A PATIENT, SUITABLE PROTEINS FOR THE INCORPORATION OF ELEMENTAL LIQUID FOOD PRODUCTS, AND METHOD FOR IMPROVING THE TASTE OF ELEMENTAL LIQUID FOOD PRODUCTS
Sandhu et al. Total parenteral nutrition and cholestasis
Kobayashi et al. Supplementation of protein-free diet with whey protein hydrolysates prevents skeletal muscle mass loss in rats
KR950700073A (en) Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acide (LNAA)
Kulkarni et al. L-Glutamic acid and glutamine: Exciting molecules of clinical interest
US5189016A (en) Nutrient compositions containing peptides and method for administering the same
Grimble Mechanisms of peptide and amino acid transport and their regulation
Johannessen et al. The acute effect of valproate on cerebral energy metabolism in mice
JP2007197363A (en) Nutritional supplement
WO2004058268A3 (en) Use of von tetrahydrobiopterine derivatives in the treatment and nutrition of patients with amino acid metabolic disorders
DE69017673D1 (en) REDUCING POST PRANDIAL LARGE NEUTRAL AMINO ACID PLASMA CONCENTRATIONS.
Taylor et al. Effect of experimental hyperphenylalaninemia on myelin metabolism at later stages of brain development
Davidova et al. Pharmacological activity of amino acids and prospects for the creation of drugs based on them
Leguina-Ruzzi et al. Glutamine: a conditionally essential amino acid with multiple biological functions
KR950010884A (en) Amino acid composition for the treatment of attack or sepsis causing inflammatory response in humans and animals
KR900013872A (en) Nutritional composition
KR920002140A (en) A method for reducing the concentration of large neutral amino acid (LNAA) in plasma after a meal.
Jonung et al. Indole amines and amino acids in various brain regions after infusion of branched chain amino acids into hepatectomized rats
Srinivasan et al. Efficacy of L-cysteine as an anti-oxidant in papain catalyzed synthesis of oligopeptides in organic solvent system
KIMURA et al. Oligopeptide mixtures produced from soy protein by enzymatic modification and their nutritional qualities evaluated by feeding tests with normal and malnourished rats
Watford et al. Dietary glutamine suppresses endogenous glutamine turnover in the rat
Maldonado et al. Differences in the serum amino acid pattern of injured and infected children promoted by two parenteral nutrition solutions

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid